34 DT Trial CAP: Background Survival in Destination Therapy Trials 2 Background Initial HeartMate II Destination Therapy (DT) trial demonstrated significant improvements in outcomes compared to randomized patients with pulsatile LVADs 1 – 68% survival at 1 year – 58% survival at 2 years Over 500 additional DT patients have been enrolled under continued access protocol (CAP) 1 Slaughter MS, Rogers JG, Milano CA et al: Advanced heart failure treated with continuous-flow left ventricular assist device.
{}